Fermenta Biotech Ltd — Important, 12-11-2025: Company Update

Fermenta Biotech Limited released its H1/FY26 Investor Presentation, highlighting robust financial and operational progress. The company reported half-year revenue of ₹280.7 Cr, up 57%, with EBITDA surging 173% to ₹69.1 Cr and profit after tax climbing 664% to ₹39.6 Cr. Strong cash generation saw operating cash flow at ₹38 Cr and free cash flow at ₹26 Cr. Key achievements include 74% volume growth in human nutrition, a patent grant for its plant-based Vitamin D3, and the board’s approval to transfer the Environment Division for ₹19 Cr. EBITDA margin was sustained at 26%, and debt-to-equity improved to 0.27x.